Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2026

Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview

• The Rituxan Hycela, Rituxan Mabthera (Rituximab) market growth in the historic period has been driven by increasing prevalence of non-hodgkin lymphoma, rising incidence of autoimmune diseases • Market expansion is supported by increasing penetration of biosimilar rituximab products, rising demand for outpatient oncology treatments • Growth Driver: Rising Prevalence Of Autoimmune Diseases Driving Growth Of The Market • Market Trend: Adoption Of Rituximab Biosimilars To Improve Patient Access And Reduce Treatment Costs • North America was the largest region in 2025.

The key promising market opportunities in the rituxan hycela, rituxan mabthera (rituximab) market include: • 50ml (Segmentation By By Type) → Expected gain of $0.21 Billion • 10ml (Segmentation By By Type) → Expected gain of $0.1 Billion

What Is Covered Under Rituxan Hycela, Rituxan Mabthera (Rituximab) Market?

Rituxan hycela and rituxan mabthera (rituximab) are monoclonal antibody therapies targeting CD20-positive B-cells. They are used to treat conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases such as rheumatoid arthritis. Rituxan hycela is a subcutaneous formulation, while rituxan mabthera is administered intravenously. The main types of rituxan hycela, rituxan mabthera (rituximab) are 10 ml and 50 ml. The 10ml vial of rituxan hycela is designed for patients who need a smaller dose of the medication. This size is often suitable for those starting treatment or requiring lower dosages, ensuring individualized care. It is administrated through the route of subcutaneous, intravenous, and parenteral and is distributed through hospital pharmacies, online pharmacies, and others. It has applications in non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others.

What Is The Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Growth Forecast?

The rituxan hycela, rituxan mabthera (rituximab) market size is expected to see rapid growth in the next few years. It will grow to $7285.24 million in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to increasing penetration of biosimilar rituximab products, rising demand for outpatient oncology treatments, expansion of subcutaneous biologics, growing focus on cost-effective biologic therapies, increasing approvals in emerging markets. Major trends in the forecast period include increasing adoption of subcutaneous rituximab formulations, rising use of monoclonal antibody therapies, expansion of indications across oncology and autoimmune disorders, growing preference for shorter administration times, enhanced focus on biosimilar competition.

What Are The Drivers Of The Rituxan Hycela, Rituxan Mabthera (Rituximab) Market?

The rising prevalence of autoimmune diseases is expected to propel the growth of the rituxan hycela, rituxan mabthera (rituximab) market going forward. Autoimmune diseases refer to conditions in which the immune system mistakenly attacks healthy tissues, leading to chronic inflammation and organ damage. The prevalence of autoimmune diseases is increasing as more healthcare providers and patients recognize the importance of early diagnosis, effective management, and access to targeted therapies to control disease progression and improve quality of life. Rituxan Hycela and rituxan mabthera (rituximab) play a crucial role in the rising prevalence of autoimmune diseases by controlling disease progression and improving patient outcomes through targeted B cell depletion. For instance, in March 2023, according to the Society for Women’s Health Research, a US-based non-profit organization, the autoimmune diseases are estimated to affect 23.5 million to 50 million. Globally, the rates of autoimmune diseases are rising by between 3 and 9 percent each year. Therefore, the rising prevalence of autoimmune diseases is driving growth of the rituxan hycela, rituxan mabthera (rituximab) industry. Rising healthcare expenditure is expected to propel the growth of the rituxan hycela and rituxan mabthera (rituximab) market going forward. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. Healthcare expenditure is rising due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure enhances access to advanced treatments such as rituxan hycela and rituxan or mabthera (rituximab), driving demand for effective therapies in oncology and autoimmune diseases. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Therefore, the rising healthcare expenditure is driving the rituxan hycela and rituxan mabthera (rituximab) market.

How Will The Drivers Impact Growth In The Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market?

• Increasing Prevalence Of Hematologic Malignancies And Autoimmune Disorders (High) – During the forecast period, the increasing prevalence of hematologic malignancies and autoimmune disorders is expected to become a key growth driver for the Rituxan Hycela, Rituxan MabThera (Rituximab) market by 2030. The growing incidence of conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other immune-mediated disorders is significantly driving demand for effective targeted therapies. Rituximab is a monoclonal antibody that targets the CD20 protein on B cells, enabling the selective elimination of abnormal or overactive B-cell populations associated with these diseases. Healthcare providers increasingly rely on Rituximab-based therapies due to their established efficacy and broad clinical utility in both oncology and autoimmune disease management. Rising disease prevalence, improved diagnostic capabilities, and expanding access to healthcare services are further contributing to treatment adoption. As the global patient population continues to grow, demand for Rituximab-based therapies is expected to increase steadily. • Growing Adoption Of Subcutaneous Formulations Such As Rituxan Hycela (High) – During the forecast period, the growing adoption of subcutaneous formulations such as Rituxan Hycela is expected to emerge as a major factor driving the expansion of the Rituxan Hycela, Rituxan MabThera (Rituximab) market by 2030. Healthcare systems are increasingly prioritizing treatment options that enhance patient convenience, reduce administration time, and improve operational efficiency. Rituxan Hycela combines Rituximab with hyaluronidase, enabling subcutaneous administration and offering a more convenient alternative to traditional intravenous infusions. This approach can significantly shorten treatment times, improve patient experiences, and optimize healthcare resource utilization within hospitals and infusion centers. In addition, healthcare providers are increasingly adopting subcutaneous therapies to streamline treatment workflows and reduce the burden on clinical staff. The growing preference for patient-centric and efficient treatment delivery methods is expected to further support market expansion. • Expanding Clinical Applications And Combination Therapy Use (High) – During the forecast period, the expanding clinical applications and combination therapy use is expected to act as a key growth catalyst for the Rituxan Hycela, Rituxan MabThera (Rituximab) market by 2030. Ongoing clinical research continues to demonstrate the effectiveness of Rituximab across a wide range of therapeutic indications and treatment settings. Rituximab is frequently used in combination with chemotherapy, immunotherapy, and other targeted therapies to improve clinical outcomes in oncology and immunology patients. The increasing incorporation of Rituximab into established treatment protocols is strengthening its role in the management of both malignant and autoimmune diseases. Furthermore, growing clinical evidence supporting broader use across diverse patient populations is encouraging healthcare providers to expand its utilization. As research efforts continue to identify new treatment opportunities and optimize existing regimens, demand for Rituximab-based therapies is expected to rise further.

How Will The Restraints Impact Growth In The Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market?

• Increasing Competition from Rituximab Biosimilars (High) – During the forecast period, increasing competition from rituximab biosimilars is expected to remain a significant restraint on the Rituxan Hycela, Rituxan MabThera (Rituximab) market. Patent expirations across major markets have accelerated the introduction of lower-cost biosimilars, creating substantial pricing pressure for originator Rituxan and MabThera products. Healthcare providers, payers, and government healthcare systems are increasingly promoting biosimilar adoption to reduce treatment costs, particularly in Europe and emerging markets. As biosimilars continue to gain physician confidence through expanding clinical evidence, regulatory approvals, and favorable reimbursement policies, market share erosion for branded Rituximab products is expected to intensify, limiting long-term revenue growth. • Risk Of Infusion-Related Reactions And Immunosuppression (High) – During the forecast period, the risk of infusion-related reactions and immunosuppression is expected to restrain the growth of the Rituxan Hycela, Rituxan MabThera (Rituximab) market. Rituximab-based therapies are associated with infusion-related adverse events, including fever, chills, hypotension, and hypersensitivity reactions, particularly during initial treatment cycles. In addition, prolonged B-cell depletion can increase the risk of infections, immunosuppression, and other serious complications, requiring careful patient monitoring and preventive management. These safety concerns may limit treatment eligibility for certain high-risk patients and increase physician caution when prescribing Rituximab. Furthermore, the need for premedication, extended monitoring, and management of adverse events can increase healthcare resource utilization and treatment costs. As a result, safety-related concerns are expected to moderate the adoption of Rituximab-based therapies and constrain market growth during the forecast period. • Declining Exclusivity and Pricing Pressure from Healthcare Cost-Containment Measures (High) – During the forecast period, declining product exclusivity and increasing pricing pressure from healthcare cost-containment measures are expected to restrain the growth of the Rituxan Hycela, Rituxan MabThera (Rituximab) market. Governments, insurance providers, and healthcare systems are increasingly implementing policies aimed at reducing biologic drug expenditures through price negotiations, tender-based procurement programs, reimbursement restrictions, and formulary optimization. These measures place significant pressure on the pricing of originator Rituximab products while encouraging broader adoption of lower-cost biosimilars and other cost-effective treatment alternatives. As pricing pressures intensify across both developed and emerging healthcare markets, revenue growth and commercial expansion for Rituxan Hycela and Rituxan MabThera are expected to remain constrained.

Key Players In The Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

Major companies operating in the rituxan hycela, rituxan mabthera (rituximab) market are F. Hoffmann-La Roche AG (Genentech Inc.)

Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Trends and Insights

Major companies are operating the rituxan hycela and rituxan mabthera (rituximab) market, focusing on developing technological advancements such as biosimilar anti-CD20 monoclonal antibodies to enhance patient access, reduce treatment costs, and maintain clinical efficacy comparable to originator rituximab. A biosimilar monoclonal antibody is a biologic drug engineered to closely mimic the reference rituximab (Rituxan/MabThera) in structure and function binding to the CD20 antigen on B cells to achieve the same therapeutic effect while offering improved affordability and accessibility. For instance, in July 2023, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, announced that its rituximab biosimilar DRL_RI (proposed brand name ITUXREDI) was accepted by the U.S. FDA for review. The product demonstrates the same amino acid sequence, mechanism of action, and clinical outcomes as the reference rituximab, and is indicated for multiple conditions, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and vasculitis, thereby expanding patient access to critical therapies.

What Defines the Rituxan Hycela, Rituxan Mabthera (Rituximab) Market?

The rituxan hycela and rituxan mabthera (rituximab) market consists of sales of MabThera 1600 mg and ritunxan hycela (rituximab and hyaluronidase human injection). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2026?

The rituxan hycela, rituxan mabthera (rituximab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rituxan hycela, rituxan mabthera (rituximab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.